OBJECTIVE: The aim of the study was to estimate the cost of major complications after liver resection and determine whether high-volume (HV) centers are cost-effective. METHODS: From 2002 to 2011, 96,107 cases of liver resection performed in the United States were identified using Nationwide Inpatient Sample. Hospitals were categorized as HV (150+ cases/yr), medium-volume (51-149 cases/yr), and low-volume (LV) (1-50 cases/yr) centers. Multivariable regression analysis identified predictors of cost. Propensity score matching comparing cases with versus without complications and costs of specific complications were estimated. Cost-effectiveness of HV centers was determined by calculating the incremental cost-effectiveness ratio. RESULTS: After propensity score matching, the occurrence of a major complication added $33,855 extra cost, increased mean length of stay by 8.7 [95% confidence interval (CI), 8.4-9] days and increased risk of death by 9.3% (all P < 0.001). The cost of most common complications was wound infection (3.8%, $21,995), renal failure (2.8%, $19,201), respiratory failure (2.7%, $25,169), and hemorrhage (3.3%, $9,180), whereas sepsis (0.8%, $33,009), gastrointestinal bleeding (0.5%, $32,835), fistula (0.2%, $27,079), and foreign body removal (0.1%, $29,404) were most costly, but less frequent. Compared with LV centers, liver resection at HV centers was associated with $5109 (95% CI, 4409-5809, P < 0.001) more cost per case, yet on average 0.54 years (95% CI, 0.23-0.86) longer survival for an incremental cost-effectiveness ratio of $9392. CONCLUSIONS: HV centers were cost-effective at performing liver resection compared with LV centers. After liver resection, complications such as surgical site infection, respiratory failure, and renal failure contributed the most to annual cost burden.
OBJECTIVE: The aim of the study was to estimate the cost of major complications after liver resection and determine whether high-volume (HV) centers are cost-effective. METHODS: From 2002 to 2011, 96,107 cases of liver resection performed in the United States were identified using Nationwide Inpatient Sample. Hospitals were categorized as HV (150+ cases/yr), medium-volume (51-149 cases/yr), and low-volume (LV) (1-50 cases/yr) centers. Multivariable regression analysis identified predictors of cost. Propensity score matching comparing cases with versus without complications and costs of specific complications were estimated. Cost-effectiveness of HV centers was determined by calculating the incremental cost-effectiveness ratio. RESULTS: After propensity score matching, the occurrence of a major complication added $33,855 extra cost, increased mean length of stay by 8.7 [95% confidence interval (CI), 8.4-9] days and increased risk of death by 9.3% (all P < 0.001). The cost of most common complications was wound infection (3.8%, $21,995), renal failure (2.8%, $19,201), respiratory failure (2.7%, $25,169), and hemorrhage (3.3%, $9,180), whereas sepsis (0.8%, $33,009), gastrointestinal bleeding (0.5%, $32,835), fistula (0.2%, $27,079), and foreign body removal (0.1%, $29,404) were most costly, but less frequent. Compared with LV centers, liver resection at HV centers was associated with $5109 (95% CI, 4409-5809, P < 0.001) more cost per case, yet on average 0.54 years (95% CI, 0.23-0.86) longer survival for an incremental cost-effectiveness ratio of $9392. CONCLUSIONS: HV centers were cost-effective at performing liver resection compared with LV centers. After liver resection, complications such as surgical site infection, respiratory failure, and renal failure contributed the most to annual cost burden.
Authors: Luka Cosic; Ronald Ma; Leonid Churilov; David Debono; Mehrdad Nikfarjam; Christopher Christophi; Laurence Weinberg Journal: Medicine (Baltimore) Date: 2019-07 Impact factor: 1.817
Authors: Mihai-Calin Pavel; Raquel Casanova; Laia Estalella; Robert Memba; Erik Llàcer-Millán; Mar Achalandabaso; Elisabet Julià; Justin Geoghegan; Rosa Jorba Journal: Syst Rev Date: 2020-12-04
Authors: Rory L Smoot; Thomas Gruenberger; Patrick Starlinger; David Pereyra; Hubert Hackl; Gregor Ortmayr; Eva Braunwarth; Jonas Santol; Sina Najarnia; Michael R Driedger; Lindsey Gregory; Roberto Alva-Ruiz; Amy Glasgow; Alice Assinger; David M Nagorney; Elizabeth B Habermann; Stefan Staetttner; Sean P Cleary Journal: Hepatology Date: 2021-03-16 Impact factor: 17.425
Authors: Bui My Hanh; Khuong Quynh Long; Le Phuong Anh; Doan Quoc Hung; Duong Tuan Duc; Pham Thanh Viet; Tran Tien Hung; Nguyen Hong Ha; Tran Binh Giang; Duong Duc Hung; Hoang Gia Du; Dao Xuan Thanh; Le Quang Cuong Journal: Lancet Reg Health West Pac Date: 2021-03-21
Authors: Daniel Heise; Jan Bednarsch; Andreas Kroh; Sandra Schipper; Roman Eickhoff; Sven Lang; Ulf Neumann; Florian Ulmer Journal: Surg Innov Date: 2021-02-10 Impact factor: 2.058